Back to Archived News
Indel Therapeutics Awarded Third Patent for Novel Antimicrobial Drug Discovery Platform
Monday, February 27, 2012
Vancouver, British Columbia -- Indel Therapeutics Inc., a biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance, announced today the issuance of its third patent by the U.S. Patent and Trademark Office further strengthening the Company's leadership position in the application of indel-based targeting for antimicrobial drug discovery.
Indel's core technology is based on an unexploited and totally novel antimicrobial targeting paradigm. This counter-intuitive approach allows the company to target proteins that are specifically excluded by currently used target selection strategies. The Indel platform identifies and targets discrete amino acid insertion or deletion differences ("indels") between essential homologous proteins that are evolutionarily conserved across the pathogen (bacteria) and humans. Based upon these structural differences, the Company can selectively target the pathogen protein with small molecules without binding to the human counterpart, thereby potentially reducing toxicity and microbial resistance. The patented indel technology opens a rich, new area for developing novel antimicrobials for the treatment of bacterial, fungal and parasitic infections and potentially viral infections.
"We are pleased that our proprietary antimicrobial drug discovery platform continues to be recognized as an innovative approach for addressing the challenges of drug resistant and hospital acquired infections," said Malcolm Kendall, the Chief Executive Officer of Indel Therapeutics. "The claims in this patent - The Diagnosis and Treatment of Infectious Diseases through Indel-differentiated Proteins - further strengthen and consolidate the Company's intellectual property and, importantly, extend the breadth our targeting approach."
About Indel Therapeutics
Indel Therapeutics Inc. is a Vancouver-based biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs focused on curing difficult-to-treat and hospital-acquired infections. These programs are based on Indel's paradigm-changing antimicrobial drug discovery platform, a patented technology that that has opened a rich, new area of antimicrobial drug targets for the treatment of infectious diseases, which has the potential to provide an advantage against drug resistance. For more information, please visit www.indelrx.com.
Back to Archived News